Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.57 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.57 |
| ▸ | MAOA | P21397 | 2/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.57 |
| ▸ | FER | P16591 | 1/20 | 0.57 |
| ▸ | LTK | P29376 | 1/20 | 0.57 |
| ▸ | CDK8 | P49336 | 1/20 | 0.57 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.57 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.49 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2589272 | 1.00 | LRRK2 (0.57) | LRRK2ACVR1MAOAMAOBPDGFRA | |
| Isoindigo SCHEMBL12386233 | 0.91 | LRRK2 (0.67) | LRRK2ACVR1MAOAMAOBPDGFRA | |
| Isoindigo SCHEMBL9899736 | 0.91 | LRRK2 (0.67) | LRRK2ACVR1MAOAMAOBPDGFRA | |
| Isoindigo SCHEMBL9899740 | 0.91 | LRRK2 (0.67) | LRRK2ACVR1MAOAMAOBPDGFRA | |
| Isoindigo SCHEMBL29349649 | 0.91 | LRRK2 (0.67) | LRRK2ACVR1MAOAMAOBPDGFRA | |
| SCHEMBL10295294 | 0.83 | LRRK2 (0.48) | LRRK2ACVR1MAOAMAOBPDGFRA | |
| SCHEMBL11890573 | 0.83 | CHEK1 (0.66) | LRRK2ACVR1MAOAMAOBPDGFRA | |
| SCHEMBL11890574 | 0.83 | FLT3 (0.54) | LRRK2ACVR1MAOAMAOBPDGFRA | |
| SCHEMBL10295101 | 0.83 | LRRK2 (0.48) | LRRK2ACVR1MAOAMAOBPDGFRA | |
| SCHEMBL11027116 | 0.83 | CHEK1 (0.66) | LRRK2ACVR1MAOAMAOBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2567225-A2 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | Virginia Tech Intellectual Properties, Inc. (US) | 2013-03-13 | — | — | EP | claimed |
| WO-2011140215-A2 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2011-11-10 | — | — | WO | claimed |
| US-20110275558-A1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2011-11-10 | — | — | US | claimed |
| EP-2567225-B1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES INC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20150241448-A1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150241448-A1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-9101573-B2 | Lanthionine synthetase component C-like proteins as molecular targets for preventing and treating diseases and disorders | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9101573-B2 | Lanthionine synthetase component C-like proteins as molecular targets for preventing and treating diseases and disorders | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| EP-2567225-A2 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | Virginia Tech Intellectual Properties, Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011140215-A2 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110275558-A1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275558-A1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | LANCL2, ACSL1, LANCL1 | LRRK2 518/4885ACVR1 431/4885MAOA 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.